Huahui Health

Company snapshot

Huahui Health is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Hepatitis Delta Virus Infection, Advanced or Unresectable Hepatocellular Carcinoma (HCC). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (2).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Huahui Health. Not investment advice.

• What is Huahui Health?

  Huahui Health is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Hepatitis Delta Virus Infection, Advanced or Unresectable Hepatocellular Carcinoma (HCC). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record

• Is Huahui Health publicly traded?

  Huahui Health appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Huahui Health develop or market?

  We link 2 drug profile(s) where Huahui Health is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/huahui-health#company-drugs.

• What are the latest developments for Huahui Health?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Huahui Health focus on?

  Huahui Health focuses on Chronic Hepatitis Delta Virus Infection, Advanced or Unresectable Hepatocellular Carcinoma (HCC) based on our analysis of their pipeline programs and drug development activities.